Read the transcript of the cc where the CEO provides guidance for 2013.
My summary is that 2013 will be a transition year, waiting for FDA to catch up with the backlog of filed ANDAs, general forecast for approval new approvals in 2013 is lower than some might have expected.
Also 2013 will require some investments and lots of work to get the Indian plant ready for FDA approval so that they can start producing lower priced generics in India for the US market and still make a good margin.
So overall 2013 expected to show much slower growth and new growth phase only expected sometime in 2014.
Yeah, the guidance for EPS was below Wall Street estimates by about .05 a share but revenues were in line which is positive. They also stated that the guidance doesn't include and potential drugs that may be approved this year. They are expecting record revenues in 2013, so I believe that YoY growth is very, very good! Lastly, the average analyst price target is around $18 and highs are $21 with most buys/outperforms/overweight ratings on the company. RBC just initiated with a HOLD and a PT of $14. I would be patient with the stock and it may be a good spot to add more on the dip.
Very strange to see a stock drop over 13 percent and see no news. There is, however, a significant number of shorts in this stock. Sold half my position yesterday and I've been in this stock since about $8. This stock is overly manipulated in my opinion. The support level over the last several months has been $12. We'll see if it holds.